Ceva Announces Vetergesic® Is Back In Stock With New Packaging And Celebrates With A Spring Offer Across Its Entire Analgesic Product Range

Ceva Animal Health has re-branded its potent, long-lasting analgesic, Vetergesic®, with new packaging following the company’s successful integration of Sogeval Animal Health. The move follows Ceva’s appointment of a new, dedicated Vetergesic manufacturing site and increased stock-holding facilities. This will guarantee a continuous long-term supply of Vetergesic in both a convenient 10ml vial for use in dogs, cats and horses and a 1ml single dose preparation for cats and dogs. “The partnership with our new manufacturing site and increased stock-holding capacity in the UK will ensure an ongoing supply of Vetergesic to veterinary practices,” comments Rob McLintock MRCVS, companion animal business unit manager at Ceva Animal Health. The company has launched a spring offer on its entire analgesic product range which also includes Meloxidyl®, Carprodyl F® and Dolagis®. For every two packs of Vetergesic, Carprodyl F or Dolagis purchased, veterinary practices will receive one pack free and for every four packs of Meloxidyl purchased veterinary practices will receive one pack free. Over and above the offer, which runs until the end of April, veterinary practices will also be able to take advantage of ongoing rebates through the new CevaSave Rebate Programme. Vetergesic, which contains buprenorphine as its active ingredient, is a centrally-acting, potent, long-lasting analgesic. It is recommended for use alongside NSAIDs for the management of mild to moderately painful surgical and traumatic conditions. It delivers a longer duration of analgesic effect compared to other veterinary opiates¹. Vetergesic is a Schedule 3 controlled drug. For further information on Ceva’s analgesic product range, including Vetergesic, or to book lunch meetings or enquire about upcoming CPD events, please contact your local Ceva territory manager, email [email protected] or call 01494 781510. ReferenceCeva Study MPK/375 BO/0302 (available on request)

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards